Compare ESI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESI | IBRX |
|---|---|---|
| Founded | 1922 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.5B |
| IPO Year | 2014 | 2015 |
| Metric | ESI | IBRX |
|---|---|---|
| Price | $39.22 | $7.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $35.56 | $12.57 |
| AVG Volume (30 Days) | 4.2M | ★ 8.5M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $2,551,200,000.00 | $113,288,000.00 |
| Revenue This Year | $21.24 | $88.59 |
| Revenue Next Year | $7.34 | $131.15 |
| P/E Ratio | $168.74 | ★ N/A |
| Revenue Growth | 3.84 | ★ 668.31 |
| 52 Week Low | $22.86 | $1.95 |
| 52 Week High | $49.25 | $12.43 |
| Indicator | ESI | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 54.53 |
| Support Level | $38.39 | $7.77 |
| Resistance Level | $39.19 | $8.46 |
| Average True Range (ATR) | 1.18 | 0.36 |
| MACD | 0.39 | 0.08 |
| Stochastic Oscillator | 92.24 | 86.95 |
Element Solutions Inc is a specialty chemicals company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. The company's reportable segments are Electronics and Industrial & Specialty. The Electronics segment, which generates maximum revenue, researches, formulates, and sells specialty chemicals and process technologies for all types of electronics hardware, from complex printed circuit board designs to semiconductor packaging. This segment's wet chemicals for metallization, surface treatments, and solderable finishes form the physical circuitry pathways, and its assembly materials, such as solder, pastes, fluxes, and adhesives, join those pathways together.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.